ClinicalTrials.gg
RecruitingNCT06815471CRAFT-WHFUpdated Nov 16, 2026

CRF2 Agonist for the Treatment of Worsening Heart Failure

A Phase 2 interventional study of COR-1167 and Placebo in Worsening Heart Failure, sponsored by Corteria Pharmaceuticals. Recruiting at 55 sites in 8 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Corteria Pharmaceuticals · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Nov 16, 2026Now RecruitingSite recruiting status changed+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Heart Failure with a site in Georgia — 18 open to participants now, 20 under way, none of them phase 3. Heart Failure · Georgia.

Planned enrollment
12th of 44
210 · median 50
Started
2025
with 3 others
Phase 2
9 of 46
1 open now
Primary completion
2027-07
later than 11 of 19 live
Registered
41st of 46
by date

Among the 46 studies in Heart Failure with a site in Georgia, this one is the 12th largest by planned enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2025, is one of 9 in phase 2, reaches primary completion later than 11 of the 19 other live ones, and was the 41st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

18 of the 46 studies in Heart Failure with a site in Georgia are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Georgia have not opened yet or have stopped. Only those recruiting at a site in Georgia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Heart Failure with a site in Georgia, or all of them as a file.
02

Study summary

This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)

Read the detailed description

This is a phase 2, randomized, double-blind, placebo-controlled study designed to assess the dose-dependent effects of the corticotropin-releasing factor type 2 (CRF2) peptide agonist, COR-1167, in subjects with WHF, defined as subjects requiring urgent administration of intravenous (i.v.) diuretics due to worsening of signs and symptoms of heart failure (HF) associated with volume overload

03

Conditions studied

  • Worsening Heart Failure

Browse trials for

Keywords

  • COR-1167
  • Hospitalised heart failure
  • WHF
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written
  • Previous diagnosis of HF documented in source records and confirmed by investigator assessment (no historical written documentation required)
  • Prescribed an oral loop diuretic for at least 1 month preceding the index event
  • NT-proBNP ≥300 pg/mL or BNP ≥100 pg/mL
  • Requires treatment with i.v. diuretics for volume overload
  • At least 1 risk factor for diuretic resistance
  • Admitted to the hospital not more than 120 hours prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Index event primarily triggered by an acute event (e.g. AMI, PE, arrhythmia)
  • Administration of i.v. inotropic therapy or i.v. vasodilators, use of mechanical ventilation, high-flow oxygen therapy, or NIV prior to randomization
  • Requirement for, or planned use of LVADs, IABP, or any type of MCS
  • History of solid organ transplant or active on a transplant list
  • SBP \<100 mmHg
  • \< 20 mL/min/1.73 m2
  • CABG, PCI, implantation of CRT, heart valve procedure or any cardiac surgery within 1 month prior to screening or planned during the study
  • Severe stenotic cardiac valvular disease
  • Severe chronic pulmonary disease requiring chronic therapy or chronic oxygen therapy (> 2 L/min)
  • Uncorrected severe hyperthyroidism or hypothyroidism
  • Severe restrictive, obstructive, or infiltrative cardiomyopathy
  • Body weight \< 70 kg at screening
  • Use of any drug(s) within 5 half-lives of screening
  • At high risk of death, defined as ≤1 year (such as participants in potential impending cardiogenic shock), or any disease that, in the opinion of the Investigator, will preclude their safe participation in this study, and will make implementation of the protocol or interpretation of the study results difficult
  • Presence of any other conditions (e.g. geographic, social) actual or anticipated, that the Investigator feels would restrict or limit the subject's participation or compliance with all study procedures
  • Participant is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study
  • Increased lactate levels > (local laboratory) at screening
  • Severe chronic liver disease (such as cirrhosis)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    COR-1167 low dose

    Drug: COR-1167

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugCOR-1167

    28-day treatment

  • DrugPlacebo

    28-day treatment

06

What researchers measure

Primary outcomes

  1. Natriuresis

    Urinary sodium excretion

    Time frame: 24 hours

  2. Body weight

    Changes in body weight

    Time frame: 7 days

  3. NT-proBNP

    Changes in NT-proBNP

    Time frame: 7 days

  4. Kansas City Cardiomyopathy Questionnaire (KCCQ)-Total Symptom Score (TSS)

    Changes in KCCQ-TSS - The score ranges from 0 to 100 with higher score indicating a better health status

    Time frame: 28 days

  5. Left Atrial Volume index (LAVi)

    Changes in LAVi - LAV-i is an index of cardiac function measured by echocardiogram

    Time frame: 2 days

07

Study locations

17 of 55 sites recruiting
  • Indiana University Health Methodist Hospital
    Indianapolis, Indiana 46202, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Wayne State University - Detroit Receiving Hospital
    Detroit, Michigan 48201, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Wayne State University - Sinai Grace Hospital
    Detroit, Michigan 48235, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Cone Health Moses Cone Hospital
    Greensboro, North Carolina 27401, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • NC Heart and Vascular Research, LLC
    Raleigh, North Carolina 27607, United States
    Recruiting
  • Ohio State University
    Columbus, Ohio 43210, United States
    Recruiting
  • South Oklahoma Heart Research, LLC
    Oklahoma City, Oklahoma 73135, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Fakultní nemocnice Brno
    Brno, 62500, Czechia
    Recruiting
  • Sdružené zdravotnické zařízení Krnov
    Krnov, 79401, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fakultní nemocnice Ostrava
    Ostrava, 70852, Czechia
    Recruiting
  • Nemocnice Slaný
    Slaný, 27401, Czechia
    Recruiting
  • Aleksandre Aladashvili Clinic LLC
    Tbilisi, 0102, Georgia
    Terminated

    Not enrolling at this site — choose another above.

  • LTD "Israeli-Georgian Medical Research Clinic Healthycore"
    Tbilisi, 0112, Georgia
    Terminated

    Not enrolling at this site — choose another above.

  • Acad. G. Chapidze Emergency Cardiology Center LTD, Department of Internal Medicine and Medical Research
    Tbilisi, 0159, Georgia
    Terminated

    Not enrolling at this site — choose another above.

  • Acad. G.Chapidze Emergency Cardiology Center, LTD, Department of Multi-center Clinical Trials
    Tbilisi, 0159, Georgia
    Terminated

    Not enrolling at this site — choose another above.

  • Bokhua Memorial Cardiovascular Center LTD
    Tbilisi, 0159, Georgia
    Terminated

    Not enrolling at this site — choose another above.

  • St. Michael's Hospital LLC
    Tbilisi, 0159, Georgia
    Terminated

    Not enrolling at this site — choose another above.

  • Tbilisi Heart and Vascular Clinic, LTD
    Tbilisi, 0159, Georgia
    Terminated

    Not enrolling at this site — choose another above.

  • Georgian Dutch Hospital
    Tbilisi, 0167, Georgia
    Terminated

    Not enrolling at this site — choose another above.

  • LTD Tbilisi Heart Center
    Tbilisi, 0186, Georgia
    Terminated

    Not enrolling at this site — choose another above.

  • Semmelweis Egyetem, Általános Orvostudományi Kar, Városmajori Szív- és Érgyógyászati Klinika
    Budapest, 1122, Hungary
    Recruiting
  • Budapesti Uzsoki Utcai Kórház, Kardiológia Osztály
    Budapest, 1145, Hungary
    Recruiting
  • Pécsi Tudományegyetem, Klinikai Központ, I. sz. Belgyógyászati Klinika
    Pécs, 7624, Hungary
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Szegedi Tudományegyetem, Általános Orvostudományi Kar, Családorvosi Intézet
    Szeged, 7625, Hungary
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Zala Vármegyei Szent Rafael Kórház, Kardiológiai Osztály
    Zalaegerszeg, 8900, Hungary
    Recruiting
  • Klinika Kardiologii i Chorób Wewnętrznych z Oddziałem Intensywnego Nadzoru Kardiologicznego (OINK), Uniwersytecki Szpital Kliniczny w Białymstoku
    Bialystok, 15-276, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • I Klinika Kardiologii, Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-214, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • SP ZOZ Szpital Uniwersytecki w Krakowie
    Krakow, 30-688, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Zespół Opieki Zdrowotnej w Klodzku, Oddzial Kardiologii
    Kłodzko, 57-300, Poland
    Recruiting
  • II Klinika Kardiologii, SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi
    Lodz, 92-213, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kliniczny Szpital Wojewódzki nr 2 im. Św. Jadwigi Królowej w Rzeszowie
    Rzeszów, 35-301, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Oddział Kliniczny Kardiologii i Intensywnej Terapii Kardiologicznej
    Torun, 87-100, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instytut Chorób Serca, Zakład Badań Klinicznych Chorób Układu Krążenia, Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu
    Wroclaw, 50-556, Poland
    Recruiting
  • Emergency County Clinical Hospital Arad, Cardiology department
    Arad, 310037, Romania
    Recruiting
  • Institutul de Urgenta pentru Boli Cardiovasculare "Prof. Dr. C.C. Iliescu", Cardiologie 1
    Bucharest, 022328, Romania
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institutul de Urgenta pentru Boli Cardiovasculare "Prof. Dr. C.C. Iliescu", Cardiologie 3
    Bucharest, 022328, Romania
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Spitalul Clinic Colentina
    Bucharest, 20125, Romania
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Craiova County Emergency Clinical Hospital
    Craiova, 200642, Romania
    Recruiting
  • Spitalul Clinic Municipal de Urgenta Timisoara
    Timișoara, 300079, Romania
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Clinical Hospital Center "Dr Dragisa Misovic Dedinje"
    Belgrade, 11000, Serbia
    Terminated

    Not enrolling at this site — choose another above.

  • Institute for Cardiovascular Diseases Dedinje
    Belgrade, 11000, Serbia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Clinical Center of Serbia, Clinic for Cardiology, Department for the testing and treatment of congenital and acquired heart defects
    Belgrade, 11000, Serbia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Clinical Center of Serbia, Clinic for Cardiology, Emergency Cardiology Department
    Belgrade, 11000, Serbia
    Recruiting
  • University Clinical Center of Serbia, Clinic for Cardiology, Heart Failure Ward
    Belgrade, 11000, Serbia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Clinical Center Kragujevac, Clinic for Cardiology
    Kragujevac, 34000, Serbia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • General Hospital Leskovac, Cardiology Department
    Leskovac, 16000, Serbia
    Withdrawn

    Not enrolling at this site — choose another above.

  • University Clinical Center Nis, Clinic for Cardiology
    Niš, 18000, Serbia
    Recruiting
  • Institute For Treatment and Rehabilitation "Niska Banja"
    Niška Banja, 18205, Serbia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitario Ramon y Cajal
    Fuencarral-El Pardo, Madrid 28034, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, Madrid 28222, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Clínico Universitario Virgen de la Arrixaca
    El Palmar, Murcia 30120, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Clínico Universitario de Valencia
    Valencia, Valencia 46010, Spain
    Recruiting
  • Hospital Universitario Hospital Virgen del Rocío
    Seville, 41013, Spain
    Recruiting
  • Consorcio Hospital General Universitario de Valencia
    Valencia, 46014, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
    Recruiting
08

References and documents

Publications

  • Rademaker MT, Charles CJ, Ellmers LJ, Lewis LK, Nicholls MG, Richards AM. Prolonged urocortin 2 administration in experimental heart failure: sustained hemodynamic, endocrine, and renal effects. Hypertension. 2011 Jun;57(6):1136-44. doi: 10.1161/HYPERTENSIONAHA.111.173203. Epub 2011 May 2. PubMed 21536988 ↗
  • Rademaker MT, Charles CJ, Nicholls MG, Richards AM. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure. Circ Heart Fail. 2009 Nov;2(6):532-40. doi: 10.1161/CIRCHEARTFAILURE.109.861336. Epub 2009 Sep 22. PubMed 19919977 ↗
  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592. Epub 2016 May 20. No abstract available. PubMed 27207191 ↗
  • Chan WY, Frampton CM, Crozier IG, Troughton RW, Richards AM. Urocortin-2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy). JACC Heart Fail. 2013 Oct;1(5):433-41. doi: 10.1016/j.jchf.2013.07.003. Epub 2013 Sep 11. PubMed 24621976 ↗
  • Rubio-Gracia J, Demissei BG, Ter Maaten JM, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, Damman K, Perez-Calvo JI, Voors AA. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol. 2018 May 1;258:185-191. doi: 10.1016/j.ijcard.2018.01.067. PubMed 29544928 ↗
  • Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014 Jan 21;129(3):399-410. doi: 10.1161/01.cir.0000442015.53336.12. No abstract available. PubMed 24446411 ↗

Individual participant data

Plan to share: No — This is not a phase 3 trial that would benefit from IPD sharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 23 months after the start.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 23 months is close to that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Dec 2026 → Jul 2027 and completion Dec 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Feb 7, 2025
StartActual
Aug 7, 2025
Primary completionEst.
Jul 2027was Dec 2026
CompletionEst.
Jul 2027was Dec 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Recruiting Reason for stopping removed
changed Nov 16, 2026
Sites
55 sites changed recruiting status (25 now active, not recruiting, 17 now recruiting, …)
Show 55 sites
  • Indiana University Health Methodist Hospital · Indianapolis, United Statesno status→Active, not recruiting
  • Wayne State University - Detroit Receiving Hospital · Detroit, United Statesno status→Active, not recruiting
  • Wayne State University - Sinai Grace Hospital · Detroit, United Statesno status→Active, not recruiting
  • Cone Health Moses Cone Hospital · Greensboro, United Statesno status→Active, not recruiting
  • NC Heart and Vascular Research, LLC · Raleigh, United Statesno status→Recruiting
  • Ohio State University · Columbus, United Statesno status→Recruiting
  • South Oklahoma Heart Research, LLC · Oklahoma City, United Statesno status→Withdrawn
  • Fakultní nemocnice Brno · Brno, Czechiano status→Recruiting
  • Sdružené zdravotnické zařízení Krnov · Krnov, Czechiano status→Active, not recruiting
  • Fakultní nemocnice Ostrava · Ostrava, Czechiano status→Recruiting
  • Nemocnice Slaný · Slaný, Czechiano status→Recruiting
  • Aleksandre Aladashvili Clinic LLC · Tbilisi, Georgiano status→Terminated
  • LTD "Israeli-Georgian Medical Research Clinic Healthycore" · Tbilisi, Georgiano status→Terminated
  • Acad. G. Chapidze Emergency Cardiology Center LTD, Department of Internal Medicine and Medical Research · Tbilisi, Georgiano status→Terminated
  • Acad. G.Chapidze Emergency Cardiology Center, LTD, Department of Multi-center Clinical Trials · Tbilisi, Georgiano status→Terminated
  • Bokhua Memorial Cardiovascular Center LTD · Tbilisi, Georgiano status→Terminated
  • St. Michael's Hospital LLC · Tbilisi, Georgiano status→Terminated
  • Tbilisi Heart and Vascular Clinic, LTD · Tbilisi, Georgiano status→Terminated
  • Georgian Dutch Hospital · Tbilisi, Georgiano status→Terminated
  • LTD Tbilisi Heart Center · Tbilisi, Georgiano status→Terminated
  • Semmelweis Egyetem, Általános Orvostudományi Kar, Városmajori Szív- és Érgyógyászati Klinika · Budapest, Hungaryno status→Recruiting
  • Budapesti Uzsoki Utcai Kórház, Kardiológia Osztály · Budapest, Hungaryno status→Recruiting
  • Pécsi Tudományegyetem, Klinikai Központ, I. sz. Belgyógyászati Klinika · Pécs, Hungaryno status→Active, not recruiting
  • Szegedi Tudományegyetem, Általános Orvostudományi Kar, Családorvosi Intézet · Szeged, Hungaryno status→Active, not recruiting
  • Zala Vármegyei Szent Rafael Kórház, Kardiológiai Osztály · Zalaegerszeg, Hungaryno status→Recruiting
  • Klinika Kardiologii i Chorób Wewnętrznych z Oddziałem Intensywnego Nadzoru Kardiologicznego (OINK), Uniwersytecki Szpital Kliniczny w Białymstoku · Bialystok, Polandno status→Active, not recruiting
  • I Klinika Kardiologii, Uniwersyteckie Centrum Kliniczne · Gdansk, Polandno status→Active, not recruiting
  • SP ZOZ Szpital Uniwersytecki w Krakowie · Krakow, Polandno status→Active, not recruiting
  • Zespół Opieki Zdrowotnej w Klodzku, Oddzial Kardiologii · Kłodzko, Polandno status→Recruiting
  • II Klinika Kardiologii, SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi · Lodz, Polandno status→Active, not recruiting
  • …and 25 more on the registry record
Nov 16, 2026
Primary completion
Dec 2026→Jul 2027
Nov 16, 2026
Study completion
Dec 2026→Jul 2027
Nov 16, 2026
Enrollment
300→210
Nov 16, 2026
Eligibility
2 inclusion criteria edited, 1 added, 1 removed; 4 exclusion criteria edited, 3 added
What changed in the criteria
Inclusion criteria
  • RemovedHeart failure hospitalization (HFH) during previous 12 months
  • AddedPrevious diagnosis of HF documented in source records and confirmed by investigator assessment (no historical written documentation required)
  • EditedNT-proBNP ≥1,000300 pg/mL or BNP ≥250100 pg/mL
  • EditedAdmitted to the hospital not more than 48120 hours prior to randomization
Exclusion criteria
  • EditedRequirement forAdministration of i.v. inotropic therapy or i.v. vasodilators, use of mechanical ventilation, high-flow oxygen therapy, or NIV prior to randomization
  • EditedBody weight < 70 kg at screening
  • EditedAt high risk of death (, defined as life expectancy ≤1 year (such as participants in potential impending cardiogenic shock) from causes other than heart failure, or any disease that, in the opinion of the Investigator, will preclude their safe participation in this study, and will make implementation of the protocol or interpretation of the study results difficult
  • EditedPresence of any other conditions (e.g. geographic, social) actual or anticipated, that the Investigator feels would restrict or limit the subject's participation or compliance with all study procedures Subject is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study
  • AddedParticipant is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study
  • AddedIncreased lactate levels > upper limit of normal (local laboratory) at screening
  • AddedSevere chronic liver disease (such as cirrhosis)
Nov 16, 2026
Interventions
Arms removed: COR-1167 intermediate dose·COR-1167 high dose
Nov 16, 2026
Contact
Study contact now listed: added f•••@corteriapharma.com · •••2998; added B•••@corteriapharma.com. See the current contact
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    55 sites changed recruiting status (25 now active, not recruiting, 17 now recruiting, …)
    Show 55 sites
    • Indiana University Health Methodist Hospital · Indianapolis, United Statesno status→Active, not recruiting
    • Wayne State University - Detroit Receiving Hospital · Detroit, United Statesno status→Active, not recruiting
    • Wayne State University - Sinai Grace Hospital · Detroit, United Statesno status→Active, not recruiting
    • Cone Health Moses Cone Hospital · Greensboro, United Statesno status→Active, not recruiting
    • NC Heart and Vascular Research, LLC · Raleigh, United Statesno status→Recruiting
    • Ohio State University · Columbus, United Statesno status→Recruiting
    • South Oklahoma Heart Research, LLC · Oklahoma City, United Statesno status→Withdrawn
    • Fakultní nemocnice Brno · Brno, Czechiano status→Recruiting
    • Sdružené zdravotnické zařízení Krnov · Krnov, Czechiano status→Active, not recruiting
    • Fakultní nemocnice Ostrava · Ostrava, Czechiano status→Recruiting
    • Nemocnice Slaný · Slaný, Czechiano status→Recruiting
    • Aleksandre Aladashvili Clinic LLC · Tbilisi, Georgiano status→Terminated
    • LTD "Israeli-Georgian Medical Research Clinic Healthycore" · Tbilisi, Georgiano status→Terminated
    • Acad. G. Chapidze Emergency Cardiology Center LTD, Department of Internal Medicine and Medical Research · Tbilisi, Georgiano status→Terminated
    • Acad. G.Chapidze Emergency Cardiology Center, LTD, Department of Multi-center Clinical Trials · Tbilisi, Georgiano status→Terminated
    • Bokhua Memorial Cardiovascular Center LTD · Tbilisi, Georgiano status→Terminated
    • St. Michael's Hospital LLC · Tbilisi, Georgiano status→Terminated
    • Tbilisi Heart and Vascular Clinic, LTD · Tbilisi, Georgiano status→Terminated
    • Georgian Dutch Hospital · Tbilisi, Georgiano status→Terminated
    • LTD Tbilisi Heart Center · Tbilisi, Georgiano status→Terminated
    • Semmelweis Egyetem, Általános Orvostudományi Kar, Városmajori Szív- és Érgyógyászati Klinika · Budapest, Hungaryno status→Recruiting
    • Budapesti Uzsoki Utcai Kórház, Kardiológia Osztály · Budapest, Hungaryno status→Recruiting
    • Pécsi Tudományegyetem, Klinikai Központ, I. sz. Belgyógyászati Klinika · Pécs, Hungaryno status→Active, not recruiting
    • Szegedi Tudományegyetem, Általános Orvostudományi Kar, Családorvosi Intézet · Szeged, Hungaryno status→Active, not recruiting
    • Zala Vármegyei Szent Rafael Kórház, Kardiológiai Osztály · Zalaegerszeg, Hungaryno status→Recruiting
    • Klinika Kardiologii i Chorób Wewnętrznych z Oddziałem Intensywnego Nadzoru Kardiologicznego (OINK), Uniwersytecki Szpital Kliniczny w Białymstoku · Bialystok, Polandno status→Active, not recruiting
    • I Klinika Kardiologii, Uniwersyteckie Centrum Kliniczne · Gdansk, Polandno status→Active, not recruiting
    • SP ZOZ Szpital Uniwersytecki w Krakowie · Krakow, Polandno status→Active, not recruiting
    • Zespół Opieki Zdrowotnej w Klodzku, Oddzial Kardiologii · Kłodzko, Polandno status→Recruiting
    • II Klinika Kardiologii, SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi · Lodz, Polandno status→Active, not recruiting
    • …and 25 more on the registry record
    Primary completion Dec 2026→Jul 2027
    Study completion Dec 2026→Jul 2027
    Enrollment 300→210
    Eligibility 2 inclusion criteria edited, 1 added, 1 removed; 4 exclusion criteria edited, 3 added
    What changed in the criteria
    Inclusion criteria
    • RemovedHeart failure hospitalization (HFH) during previous 12 months
    • AddedPrevious diagnosis of HF documented in source records and confirmed by investigator assessment (no historical written documentation required)
    • EditedNT-proBNP ≥1,000300 pg/mL or BNP ≥250100 pg/mL
    • EditedAdmitted to the hospital not more than 48120 hours prior to randomization
    Exclusion criteria
    • EditedRequirement forAdministration of i.v. inotropic therapy or i.v. vasodilators, use of mechanical ventilation, high-flow oxygen therapy, or NIV prior to randomization
    • EditedBody weight < 70 kg at screening
    • EditedAt high risk of death (, defined as life expectancy ≤1 year (such as participants in potential impending cardiogenic shock) from causes other than heart failure, or any disease that, in the opinion of the Investigator, will preclude their safe participation in this study, and will make implementation of the protocol or interpretation of the study results difficult
    • EditedPresence of any other conditions (e.g. geographic, social) actual or anticipated, that the Investigator feels would restrict or limit the subject's participation or compliance with all study procedures Subject is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study
    • AddedParticipant is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study
    • AddedIncreased lactate levels > upper limit of normal (local laboratory) at screening
    • AddedSevere chronic liver disease (such as cirrhosis)
    Interventions Arms removed: COR-1167 intermediate dose·COR-1167 high dose
    Contact Study contact now listed: added f•••@corteriapharma.com · •••2998; added B•••@corteriapharma.com. See the current contact
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06815471
Lead sponsor
Corteria Pharmaceuticals
Collaborators
Worldwide Clinical Trials
Responsible party
Sponsor
First posted
Feb 7, 2025
Start date
Aug 7, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Corteria Chief Medical Officer
Contact
francesca.lawson@corteriapharma.com
610-787-2998
Clinical Operations Director
Contact
Brian.Sontag@Corteriapharma.com
Jeffrey Testani, MD
study chair · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion